Cardiex at DIA 2024: Pioneering Vascular Biomarkers in Drug Development 

Wrapping up a successful summer trade show season, the Cardiex team attended the Drug Information Association (DIA) Global Annual Meeting in San Diego from June 16 to 20. This premier event brought together industry leaders from the pharmaceutical, biotechnology, and medical device sectors to discuss the latest trends, innovations, and regulatory updates in healthcare.

The DIA Global Annual Meeting offered Cardiex an essential opportunity to engage with industry leaders, share our technological advancements, and discuss the role of digital vascular biomarkers in shaping the future of healthcare.

Cardiex’s booth was a focal point of the event, showcasing our innovative suite of FDA-cleared products, including the SphygmoCor XCEL, the Oscar 2 Ambulatory Blood Pressure Monitor, and the soon-to-be-released CONNEQT Pulse digital vascular biomarker monitor. These devices are essential for comprehensive arterial health assessments, providing critical data for clinical trials, patient care, and research.

“DIA never disappoints and is a pillar conference in the drug development industry,” said Brian Schaechter, Cardiex’s Senior Director of Sales – Pharmaceutical. “Our focus on the importance of vascular biomarkers in designing effective and safe therapeutic candidates was well received. The attendees were amazed that our devices cover all clinical trial modalities, including office, home, and 24-hour ambulatory monitoring with the same easy-to-use, non-invasive SphygmoCor technology.”

The team offered complimentary arterial health assessments, seeing more than 200 attendees visit the Cardiex booth. Each visitor walked away with valuable insights into their arterial health. Everyone who participated particularly appreciated the convenience and ease of the vascular biomarker test.

For the latest updates and to connect with our team at future events, visit our Events & Tradeshows page and follow us on social media. Don’t miss the latest news and insights—subscribe to our monthly newsletter today.